Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer

被引：1
|
作者：
Rosell, Rafael [1 ,2 ,3 ]
Gonzalez-Cao, Maria [3 ]
Codony-Servat, Jordi [4 ]
Molina-Vila, Miguel Angel [4 ]
Mayo de las Casas, Clara [4 ]
Ito, Masaoki [5 ]
机构：
[1] Germans Trias & Pujol Res Inst IGTP, Badalona, Spain
[2] Catalan Inst Oncol ICO, Badalona, Spain
[3] Quiron Dexeus Univ Hosp, Inst Oncol Dr Rosell IOR, Barcelona, Spain
[4] Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Barcelona, Spain
[5] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan
来源：
TRANSLATIONAL CANCER RESEARCH | 2023年 / 12卷 / 03期
关键词：
BRAF; ROS1; mitogen-activated protein kinase (MAPK); RAF; missense mutations; RASGRF1;
D O I：
10.21037/tcr-22-2888
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：456 / 460
页数：5
相关论文
共 50 条
  • [1] Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
    Rotow, J.
    Patel, J.
    Hanley, M.
    Yu, H.
    Goldman, J.
    Nechustan, H.
    Scheffler, M.
    Awad, M.
    Clifford, S.
    Santucci, A.
    Silva, L.
    Tupper, R.
    Oxnard, G.
    Kherani, J.
    Drilon, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S230 - S230
  • [2] Osimertinib in EGFR-mutant non-small cell lung carcinoma
    Lorenz, Judith
    [J]. PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
  • [3] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [4] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ortega-Franco, Ana
    Rafee, Shereen
    [J]. ONCOLOGY AND THERAPY, 2022, 10 (01) : 13 - 22
  • [5] CARDIOVASCULAR EVENTS IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER ON OSIMERTINIB
    Peleg, Ariel
    Ibtida, Ishmam
    Liu, Jennifer
    Steingart, Richard
    Yu, Anthony
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3288 - 3288
  • [6] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ana Ortega-Franco
    Shereen Rafee
    [J]. Oncology and Therapy, 2022, 10 : 13 - 22
  • [7] Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
    Ricciuti, Biagio
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 : S249 - S252
  • [8] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Soei Gen
    Ichidai Tanaka
    Masahiro Morise
    Junji Koyama
    Yuta Kodama
    Akira Matsui
    Ayako Miyazawa
    Tetsunari Hase
    Yoshitaka Hibino
    Toshihiko Yokoyama
    Tomoki Kimura
    Norio Yoshida
    Mitsuo Sato
    Naozumi Hashimoto
    [J]. BMC Cancer, 22
  • [9] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Gen, Soei
    Tanaka, Ichidai
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Hashimoto, Naozumi
    [J]. BMC CANCER, 2022, 22 (01)
  • [10] Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers
    Offin, Michael
    Somwar, Romel
    Rekhtman, Natasha
    Benayed, Ryma
    Chang, Jason C.
    Plodkowski, Andrew
    Lui, Allan J. W.
    Eng, Juliana
    Rosenblum, Marc
    Li, Bob T.
    Riely, Gregory J.
    Rudin, Charles M.
    Kris, Mark G.
    Travis, William
    Drilon, Alexander
    Arcila, Maria E.
    Ladanyi, Marc
    Yu, Helena A.
    [J]. JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 12
12345